Objective To establish the drug use evaluation criteria of apatinib and to apply it for evaluation of clinical rational drug use.Methods Based on the apatinib label instruction, through Delphi method, the drug use evaluation of apatinib was established with reference to clinical practice guidelines of common malignant tumor and expert consensuses. According to this standard, the drug use of inpatients who have used apatinib in Jiangsu Provincial Hospital of Chinese Medicine from January 1, 2022 to December 31, 2022 was retrospectively analyzed.Results A total of 169 patients receiving apatinib were collected, and 320 cases of corresponding medical records were included. 35 cases had their use of apatinib fully met the drug use evaluation criteria, but 285 cases did not. The irrational use rate was 89.06%. Among them, the common unreasonable indexes were usage and dosage (78.44%), indications (63.31%) and medication monitoring (41.25%).Conclusion The established evaluation standard for the use of apatinib fully covers the evaluation index of rational drug use, and has strong clinical applicability. According to the established apatinib evaluation standard, it can be found that the unreasonable rate of drug use in our hospital is relatively high, and there are problems such as incorrect usage and dosage, ultra-adaptive medication, and lack of medication monitoring.